Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22801937 | 1.00 | PIK3R1 (0.35) | PIK3R1PIK3CAKAT6AAURKAPDPK1 | |
| SCHEMBL22822713 | 0.89 | PIK3R1 (0.35) | PIK3R1PIK3CAKAT6AAURKAPDPK1 | |
| SCHEMBL22822874 | 0.89 | PIK3R1 (0.35) | PIK3R1PIK3CAKAT6AAURKAPDPK1 | |
| SCHEMBL21274041 | 0.87 | KDM1A (0.38) | PIK3R1PIK3CAKAT6AAURKAPDPK1 | |
| SCHEMBL22802032 | 0.87 | KDM1A (0.38) | PIK3R1PIK3CAKAT6AAURKAPDPK1 | |
| SCHEMBL22822420 | 0.83 | GSK3B (0.37) | PIK3R1PIK3CAKAT6AAURKAPDPK1 | |
| SCHEMBL22822712 | 0.83 | GSK3B (0.37) | PIK3R1PIK3CAKAT6AAURKAPDPK1 | |
| SCHEMBL22822764 | 0.82 | PDE10A (0.36) | PIK3R1PIK3CAAURKAPDPK1AURKB | |
| SCHEMBL22822445 | 0.82 | PIK3R1 (0.37) | PIK3R1PIK3CAKAT6AAURKAPDPK1 | |
| SCHEMBL22822753 | 0.82 | PIK3R1 (0.37) | PIK3R1PIK3CAKAT6AAURKAPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | EVOTEC (UK) LTD (GB) | 2020-12-24 | — | — | US | disclosed |
| EP-3752150-A1 | PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES | UCB Biopharma SRL (BE) | 2020-12-23 | — | — | EP | disclosed |
| CN-112105357-A | Pharmaceutically acceptable 6,5 heterobicyclic derivatives | UCB生物制药有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| WO-2019158731-A1 | PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | STING1, IRF3, NFATC1 | PIK3R1 116/4885PIK3CA 595/4885KAT6A 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.